A deep dive with Linda Orzolek on lab leadership, startup scaling, and how her 20+ years in transcriptomics are helping drive accessible innovation in personalized medicine—without a PhD.
Few people have influenced the field of transcriptomics and lab operations in Maryland as much as Linda Orzolek—and she did it all without a PhD. Her career spans more than two decades at Johns Hopkins University, where she led the transformation of the core lab from microarrays to spatial transcriptomics. Today, she brings that same momentum to OMAPix Inc., a fast-growing CRO in Frederick focused on personalized and precise medicine.
Q: What sparked your passion for life sciences?
It started with an excellent high school biology teacher during her sophomore year, who ignited her love for genetics. “That was it—I never looked back,” Linda recalls.
That spark grew into a passion during her undergrad at LaSalle University, where a standout internship with the Department of Defense solidified her interest in molecular biology. “It all started from looking at transcriptional profiles and changes,” she says. “After that, I never wanted to do anything else.”
Although she considered pursuing a PhD, Linda chose a different path. “I was advised early on by several PhDs: ‘Don’t get your PhD. It’s not worth it.’ So I didn’t,” she explains. “But what I found was the value in guiding people in their research, in having my hands in everything.”
Q: What drew you to OMPAiX after years in academia?
After more than 20 years at Hopkins, Linda wanted a challenge that would allow her to apply everything she’d learned on a bigger scale. “I came to OMAPix to build something new, but grounded in everything I’ve learned,” she says. “What hooked me was that everyone here has the same mission: advancing personalized medicine.”
Since joining in October 2024, she has expanded the company’s lab services from one technology to more than 14, rapidly scaling OMAPix’s capabilities without sacrificing quality. She calls OMAPix a “concierge CRO,” explaining that researchers today need more than a vendor—they need a trusted partner, an extension of their lab.
Q: How has Frederick shaped the way you operate?
Frederick has been a strategic advantage, offering proximity to major hospitals and research institutions while keeping the costs of building a lab and growing a team manageable. It also enables Linda to deliver on her promise of hands-on service. For customers at Hopkins and the University of Maryland, she picks up samples herself—avoiding FedEx shipments and dry ice delays. “They know their samples are safe,” she says.
Q: What’s one operational truth you wish more vendors understood?
Science moves at its own pace, and that pace is often unpredictable. “From sample quality to clinical trial delays, research timelines can’t always be forecasted,” Linda explains. “You can’t put rigid timeframes on this work. There’s a lot of ‘hurry up and wait,’ and you need vendors and investors who understand that.”
Q: Has there been a defining moment that shaped your leadership approach?
For Linda, that moment came when she saw how quickly OMAPix scaled. “When I started, we had one technology. Now we offer over 14,” she says. Bringing a lifetime of experience to the table allowed her to cut out costly trial-and-error, saving the company significant time and money. “It wouldn’t have happened without the location and the foundation I was able to build,” she adds.
Q: What’s been the biggest challenge in building lab operations so quickly?
“Money—it’s a lousy time to be in research,” Linda says bluntly. Without IP or proprietary products, OMAPix depends on investors who understand the value of enabling research rather than owning it. Her pitch is simple: “It costs more when it fails. What we offer is confidence and capability backed by decades of experience.”
Q: How do you tap into the expertise needed to grow sustainably?
Linda relies on two decades of partnerships and vendor connections. “If I don’t know the answer, someone I trust does,” she says. From renting instrumentation through vendor partnerships to working directly with clients to develop protocols, this network is a core part of how OMAPix scales smartly without wasting time or money.
Closing Thoughts
Linda’s journey is a testament to what’s possible when experience meets entrepreneurial ambition. She may not hold a PhD, but her knowledge, leadership, and grit have positioned OMAPix as more than a lab—they’re redefining what a CRO can be.
Stories like Linda Orzolek’s remind us that the strength of a biotech ecosystem isn’t measured only by capital raised or technologies launched. It’s also shaped by the operators who build the infrastructure, culture, and trust that innovation relies on.
As the BioHealth Capital Region continues to grow, leaders like Linda exemplify a broader vision of success—one rooted in service, operational excellence, and human-centered leadership. The future of life sciences depends not just on breakthrough ideas, but on the people and platforms that turn those ideas into real-world impact.
